Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106818 | 0.88 | F10 (0.58) | F10 | |
| SCHEMBL6107653 | 0.84 | F10 (0.52) | CHRM1CHEK1F10 | |
| SCHEMBL6106827 | 0.84 | F10 (0.52) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL5759686 | 0.84 | F10 (0.58) | KCNMA1KDM4EGAAHPGDALOX15 | |
| SCHEMBL6107029 | 0.82 | F10 (0.55) | ALOX15CHEK1F10 | |
| SCHEMBL6106785 | 0.80 | F10 (0.52) | TSHRCHRM1CHRM3CHRM2CHEK1 | |
| SCHEMBL6107921 | 0.80 | F10 (0.52) | ALOX15TSHRCHRM1CHEK1F10 | |
| SCHEMBL5758733 | 0.80 | KDM4E (0.48) | KCNMA1KDM4EGAAHPGDALOX15 | |
| SCHEMBL7381197 | 0.80 | KCNMA1 (0.52) | KCNMA1KDM4EGAAHPGDALOX15 | |
| SCHEMBL6107299 | 0.78 | F10 (0.51) | CHEK1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140881-B1 | ANTITHROMBOTIC AMIDES | LILLY CO ELI (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6780878-B2 | ANTICOAGULANTS; CARDIOVASACULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-6716839-B2 | INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6716855-B2 | INHIBITOR OF FACTOR XA; N1-(BENZOYL)-N2-(1-(4-PYRIDYL)PIPERIDIN-4-YL-METHYL)-1,2-BENZENDIAMINE HIGH BIOAVAILABILITY | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6710057-B2 | INHIBITORS OF FACTOR XA, AS ANTICOAGULANTS FOR PROPHYLAXIS AND TREATMENT OF THROMBOEMBOLIC DISORDERS | ELI LILLY AND COMPANY | 2004-03-23 | — | — | US | disclosed |
| US-20030212069-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-11-13 | — | — | US | disclosed |
| US-20030199504-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030199505-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030191153-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-09 | — | — | US | disclosed |
| US-6610704-B1 | Inhibit factor Xa | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| EP-1140881-A1 | ANTITHROMBOTIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039111-A1 | ANTITHROMBOTIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191153-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | KCNMA1 1137/4885KDM4E 2930/4885GAA 1577/4885 |
| US-20030199504-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | KCNMA1 1137/4885KDM4E 2930/4885GAA 1577/4885 |
| US-20030212069-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | KCNMA1 1137/4885KDM4E 2930/4885GAA 1577/4885 |
| US-20030199505-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | KCNMA1 1137/4885KDM4E 2930/4885GAA 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.